glp-1 liver fibrosis Current status of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic disease: A clinical perspective GLP-1 Shows Promise for Patients

Future moves could widen this coverage difference, significantly weakening the TFL benefit

The question is no longer whether to integrate connected devices into GLP-1 trials, but how to do so in a way that ensures data integrity, operational scalability, and regulatory readiness

Binding of GIP to its receptor also stimulates glucose-dependent insulin secretion and produces a greater proportion of the incretin effect than GLP-1 (about 45% for GIP and 29% for GLP-1) [133]

Small, frequent meals may be better tolerated than larger portions given the delayed gastric emptying induced by GLP-1 medications

The GLP-1 Access Gap: Mapping Who Can Actually Afford Americas Miracle Weight-Loss Drugs Published 2/4/2026 Author: Andrew Reed, Assoc

In the UK and the US, that means a BMI of 30 or more, or 27 if you also have a weight-related condition like high blood pressure or type 2 diabetes